Bronchodilatatorische Therapie der COPD

A.-M. Kirsten; H. Watz; H. Magnussen

doi:10.1055/s-0033-1360019

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2014; 139(06): 264-267
DOI: 10.1055/s-0033-1360019

Pneumologie | Commentary

Pneumologie

Bronchodilatatorische Therapie der COPD

Bronchodilator therapy of COPD

Authors

A.-M. Kirsten

¹Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf, Airway Research Center North, Mitglied des Deutschen Zentrum für Lungenforschung
H. Watz

¹Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf, Airway Research Center North, Mitglied des Deutschen Zentrum für Lungenforschung
H. Magnussen

¹Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf, Airway Research Center North, Mitglied des Deutschen Zentrum für Lungenforschung

Abstract

Schlüsselwörter

COPD - Bronchodilatatoren - LABA - LAMA

Keywords

COPD - bronchodilators - LABA - LAMA

Full Text

References

Literatur
1 Beier J, Kirsten AM, Mruz R et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD 2013; 10: 511-522
2 Decramer M, Chapman KR, Dahl R et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013; 1: 524-533
3 Dransfield MT, Bourbeau J, Jones PW et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled studies. Lancet Respir Med 2013; 1: 210-223
4 Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J 2013; 34: 2795-2803
5 Roche N, Small M, Broomfield S et al. Real World COPD: Association of Morning Symptoms with Clinical and Patient Reported Outcomes. COPD 2013; 10: 679-686
6 Singh S, Loke YK, Enright P et al. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax 2013; 68: 114-116
7 Singh S, Loke YK, Enright PL et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011; 342: d3215
8 Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res 2013; 14: 49
9 Vestbo J, Hurd SS, Agusti AG et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365
10 Vogelmeier C, Hederer B, Glaab T et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093-1103
11 Wedzicha JA, Decramer M, Ficker JH et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomized, double-blind, parallel-group study. Lancet Respir Med 2013; published online April
12 Wedzicha JA, Decramer M, Seemungal TA. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J 2012; 40: 1545-1554
13 Wise RA, Anzueto A, Cotton D et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013; 369: 1491-1501